GlassScriptPhysician profile
Roy W Langley
NPI 1750394755
$5,073.59
in general payments reported to CMS, 2019-2025
11 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $3,400 · 2022: $15.28 · 2023: $63.75 · 2024: $24.11 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.43 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,800.00 | 2019-2020 | |
| Dexcom, INC. | $68.33 | 2025 | Dexcom G6 Transmitter |
| Amphastar Pharmaceuticals, INC. | $37.03 | 2025 | |
| Sequel Med Tech, LLC | $28.21 | 2025 | Twiist |
| Insulet Corporation | $24.45 | 2023 | Omnipod |
| Abbott Laboratories | $24.11 | 2024 | Freestyle Libre 3 |
| Beta Bionics, INC. | $20.80 | 2023 | Ilet Bionic Pancreas |
| Medtronic Minimed, INC. | $20.61 | 2019 | |
| Medtronic, INC. | $18.50 | 2023 | Minimed 780g |
| Novo Nordisk INC | $16.27 | 2025 | Ozempic |
| Amgen INC. | $15.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.